NCT04094610 2025-11-19
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT05828303 2025-04-01
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT05071183 2024-04-02
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated
NCT05828277 2023-09-26
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn